ArticleViruses2010
Development of viral vectors for use in cardiovascular gene therapy.
Article in Viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Angiogenic Gene Therapy for Lower Extremity Ischemia: Experimental Advances and Clinical Experience.Cells · 2026Review
- Macrophage-specific circular RNA circHIPK2, inflammation, and fibrosis after myocardial infarction.European heart journal · 2026Article
- Oncolytic Virotherapy in Solid Tumors: A Current Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Integrative Genetic Approach Facilitates Precision Strategies for Acute Myocardial Infarction.Genes · 2023Review
- Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Remuscularization with triiodothyronine and βScientific reports · 2022Article
- mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.Frontiers in bioengineering and biotechnology · 2022Review
- Recent advances in gene therapy for atrial fibrillation.Journal of cardiovascular electrophysiology · 2021Review
- Inhibition of Neointima Hyperplasia, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries by HVJ Envelope Vector-Mediated Delivery of Superoxide Dismutase Gene.Translational stroke research · 2019Article
- Adeno-Associated Virus Mediated Gene Delivery: Implications for ScalableFrontiers in physiology · 2019Article
- Gene Therapy Approaches to Biological Pacemakers.Journal of cardiovascular development and disease · 2018Review
- Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy.International journal of molecular sciences · 2018Review
- Prevention of Atrial Fibrillation by Using Sarcoplasmic Reticulum Calcium ATPase Pump Overexpression in a Rabbit Model of Rapid Atrial Pacing.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation.Cardiovascular research · 2015Review
- Review
- Cardiac applications of optogenetics.Progress in biophysics and molecular biology · 2014Review
- Improved animal models for testing gene therapy for atherosclerosis.Human gene therapy methods · 2014Article
- Optogenetics' promise: pacing and cardioversion by light?Future cardiology · 2014Article
- Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease represents the most common cause of mortality in the developed world but, despite two decades of promising pre-clinical research and numerous clinical trials, cardiovascular gene transfer has so far failed to demonstrate convincing benefits in the clinical setting. In this review we discuss the various targets which may be suitable for cardiovascular gene therapy and the viral vectors which have to date shown the most potential for clinical use. We conclude with a summary of the current state of clinical cardiovascular gene therapy and the key trials which are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.